Engineered red blood cells as an off-the-shelf allogeneic anti-tumor therapeutic

Xuqing Zhang(Rubius Therapeutics (United States)), Tiffany F. Chen(Rubius Therapeutics (United States))

Nature Communications

May 11, 2021

10.1038/s41467-021-22898-3

Cited by 58

Related Papers

Combination of entecavir with thymosin alpha-1 in HBV-related compensated cirrhosis: a prospective multicenter randomized open-label study

|Expert Opinion on Biological Therapy|2018|44

On‐treatment changes of liver stiffness at week 26 could predict 2‐year clinical outcomes in <scp>HBV</scp>‐related compensated cirrhosis

|Liver International|2017|41

Dexamethasone protects normal human liver cells from apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand by upregulating the expression of P-glycoproteins

|Molecular Medicine Reports|2012|13